
News|Articles|November 29, 2012
Study: Similar safety, efficacy with dabigatran versus warfarin in diabetic patients with Afib
Patients with nonvalvular atrial fibrillation (NVAF) who also have diabetes experienced similar safety and efficacy with dabigatran etexilate mesylate (Pradaxa) 150 mg or dabigatran 110 mg relative to warfarin, in comparison to patients without diabetes who have NVAF, according to data presented at American Heart Association's Scientific Sessions 2012.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicare Part D redesign reshapes market
2
A conversation with Tiffany Phung, Pharm.D., CSP, about how patient outcomes drive specialty pharmacy strategy
3
The sleep doctor who lives with a disorder he treats
4
Managing Chronic Disease Shouldn't Feel Like a Full-Time Job
5




















